Allogene Therapeutics, Inc. (ALLO) stock
ALLONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 3/30
$0.81−0.03 (-3.78%)
Close on Nov 16, 2026Market cap $278.81MP/E –Yield 0.00%
Allogene Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for Allogene Therapeutics
Allogene Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?